Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome

T. Krejsgaard, L. M. Gjerdrum, E. Ralfkiaer, B. Lauenborg, K. W. Eriksen, A. M. Mathiesen, L. F. Bovin, R. Gniadecki, C. Geisler, L. P. Ryder, Q. Zhang, M. A. Wasik, N. Ødum, A. Woetmann*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Sézary syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma. During disease progression, immunodeficiency develops; however, the underlying molecular and cellular mechanisms are not fully understood. Here, we study the regulatory T cell (Treg) function and the expression of FOXP3 in SS. We demonstrate that malignant T cells in 8 of 15 patients stain positive with an anti-FOXP3 antibody. Western blotting analysis shows expression of two low molecular splice forms of FOXP3, but not of wild-type (wt) FOXP3. The malignant T cells produce interleukin-10 and TGF-β and suppress the growth of non-malignant T cells. The Treg phenotype and the production of suppressive cytokines are driven by aberrant activation of Jak3 independent of the FOXP3 splice forms. In contrast to wt FOXP3, the low molecular splice forms of FOXP3 have no inhibitory effect on nuclear factor-κB (NF-κB) activity in reporter assays which is in keeping with a constitutive NF-κB activity in the malignant T cells. In conclusion, we show that the malignant T cells express low molecular splice forms of FOXP3 and function as Tregs. Furthermore, we provide evidence that FOXP3 splice forms are functionally different from wt FOXP3 and not involved in the execution of the suppressive function. Thus, this is the first description of FOXP3 splice forms in human disease.

    Sider (fra-til)2230-2239
    Antal sider10
    Udgave nummer12
    StatusUdgivet - 1 jan. 2008


    Udforsk hvilke forskningsemner 'Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome' indeholder.